Japan Lifeline Co., Ltd.【JP:7575】Stock Price

Japan Lifeline is a medical device manufacturer, importer, and distributor specializing in cardiovascular products. The company handles cardiac pacemakers and ICDs (implantable cardioverter-defibrillators) used to treat heart arrhythmias, as well as CRT-D devices (biventricular pacemakers with defibrillation capability). The company sources and sells these products.

The company's core products also include EP (electrophysiology) catheters used for arrhythmia diagnosis and ablation catheters used for arrhythmia treatment. Japan Lifeline manufactures, sources, and sells these products, with some units manufactured by JLL Malaysia Sdn. Bhd. and sold to the company.

In the cardiovascular segment, key products include artificial blood vessels, Frozen Elephant Trunk devices, and stent grafts used to treat aortic disease. Japan Lifeline manufactures, sources, and sells these products.

In the cerebrovascular segment, main products include embolization coils, thrombectomy catheters, and stent retrievers used in cerebrovascular interventional procedures. The company handles sourcing and sales of these products.

In the gastrointestinal field, key products include colonic stents, gastroduodenal stents, radiofrequency ablation electrodes for hepatic cancer treatment, and biliary stent tubes used in digestive disease treatment. Japan Lifeline manufactures, sources, and sells these products, with some units manufactured by JLL Malaysia Sdn. Bhd.

Japan Lifeline announced its medium-term management plan for 2024-2028 in May 2023, targeting growth in the medical device industry. The plan sets numerical targets for sales revenue, operating profit margin, ROIC, and EPS, with three key strategic priorities: "expansion into new therapeutic areas," "continuous introduction of competitive products," and "strengthened capital-efficient management."

For expansion into new therapeutic areas, Japan Lifeline is leveraging its cardiovascular expertise to enter the gastrointestinal and cerebrovascular markets. By 2028, the company aims to achieve 4.5 billion yen in cerebrovascular sales and 3.5 billion yen in gastrointestinal sales, while also planning entry into the structural heart disease market. This strategy aims to establish new revenue pillars.

For continuous introduction of competitive products, the company is utilizing its capabilities as both a manufacturer and distributor to launch new offerings. While maintaining market share in intracardiac defibrillation catheters and FET products, Japan Lifeline is expanding market penetration of femoral vein hemostasis devices. Additionally, through joint development of PFA products, the company is pursuing market introduction of new treatment methods.

To improve capital efficiency, Japan Lifeline has set a target ROIC of 13% or higher. The company is implementing appropriate capital allocation, clarifying cash allocation and shareholder return policies, ensuring financial soundness, and advancing growth investments to achieve sustainable business expansion.

Furthermore, Japan Lifeline has established "expansion of global sales and promotion of OEM manufacturing" as a new strategic priority. The company is expanding its cardiovascular and gastrointestinal products into overseas markets, particularly broadening distribution channels in the Middle East and Asia. Through OEM manufacturing, Japan Lifeline is creating new business opportunities and pursuing long-term growth.